RxCapital – RxCelerate

RxCAPITAL

RxCapital is the investment arm of RxCelerate. We are a balance sheet investor, which means we do not have fixed timescales or investment sizes, nor do we have limitations on geography, technology or stage of companies in which we invest.

Importantly, we are pure financial investors – we do not invest in our clients, through non-financial instruments such as risk-sharing, nor do we expect the companies we invest in to use RxCelerate services, although they are free to do so if they wish. Instead, we invest in technologies that we consider transformational in their space.

We invest in therapeutic and diagnostic assets and platform technologies, as well as enabling technologies for drug discovery or development (including digital). We do not invest in medical devices or direct-to-consumer interventions (such as apps). In addition, we do not lead investment rounds.

Typically, we invest in companies that are well known to our team – but we always welcome new opportunities to review as long as the technology is truly transformational. You can get in touch with us through rxcapital@rxcelerate.com

Our Team

There are currently five members of our Investment Committee:

David Grainger

David is Executive Chairman at RxCelerate, as well as Chief Innovation Officer at Centessa Pharmaceuticals (NASDAQ: CNTA) and a Venture Advisor at Medicxi

Jill Reckless

Jill is currently Founder and Chief Executive Officer at RxCelerate

Nick Tait

Nick is Chief Financial Officer at RxCelerate Group, as well as Financial Director at The Cambridge Partnership

Nigel Ramsden

Nigel is the Executive Vice President at RxChemistry

Jonny Finlay

Jonny is a Co-Founder and Director at RxBiologics, as well as Founder and Chief Executive Officer of Lockbody Therapeutics and Granular Therapeutics

Together, they have more than a century of experience in drug discovery, development and commercialisation, across a range of modalities from small molecules to biologics and nucleic acids

Our Portfolio

Investments include:

Rivus is a privately-held clinical-stage pharmaceutical company based in Charlottesville, VA, USA, developing treatments for obesity-related diseases, including NASH, type 2 diabetes and heart failure. Its lead product candidate, HU6, is a pro-drug of dinitrophenol that safely uncouples mitochondria leading to metabolic inefficiency helping rid the body of excess calories. In a recent Ph2 clinical trial, HU6 delivered significant weight loss and improvement on multiple metabolic end-points in a population of overweight subjects, with an exceptional safety and tolerability profile. Rivus also has a platform of next-generation sub-maximal uncoupler molecules in preclinical development.

Rivus Pharmaceuticals

Dynamic Biosensors (DBS) is a private company based in Munich, Germany, which has developed and commercialised an entirely novel biosensor, SwitchSENSE™, that detects molecular interactions. With considerably advantages over the market leader, surface plasmon resonance, unlocking a wide range of new applications within drug discovery and development, the Helix™ system, that delivers SwitchSense™ to the marketplace, has already been sold to a number of lighthouse customers including academic labs and large pharmaceutical companies in Europe, the US and Asia.

Dynamic Biosensors

Centessa is a publicly-listed (NASDAQ:CNTA) clinical-stage pharmaceutical company with a world-class pipeline of drug candidates, including lixivaptan (in a Phase 3 pivotal trial for autosomal-dominant polycystic kidney disease; ADPKD), serpin PC (in late-stage development for the treatment of various haemophilias) and ZF874 (in Ph2 proof of clinical concept studies for the treatment of alpha-1-antitrypsin deficiency; AATD).

Centessa